Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year

DSC Meridian Capital disclosed it fully liquidated its 510,090-share stake in Bausch + Lomb (NYSE: BLCO) in Q3, an estimated $6.6 million sale that reduced a position that had represented roughly 1.35% of its reportable AUM to zero. Bausch + Lomb reported improving fundamentals—Q3 revenue rose 7% YoY to $1.28 billion and adjusted EBITDA increased to $243 million with management nudging full‑year adjusted EBITDA guidance higher—while TTM revenue is about $5.0 billion and TTM net loss ~$305 million; the stock has lagged, down ~9% over the past year, indicating the exit reflects investor positioning and sentiment rather than clear deterioration in operations.

Analysis

Market structure: DSC Meridian’s full exit from BLCO is a small but visible instantiation of investor rotation away from idiosyncratic healthcare names toward commodity/infrastructure exposures (their top holdings include BKLN, CORZ, TECK). Near-term selling pressure is limited — the disclosed $6.6M trade is ~1.35% of the fund’s reportable AUM — but the signal matters: other quant/momentum funds may treat the filing as confirmation to trim, amplifying volatility for BLCO over the next 1–3 months. For suppliers and competitors, steady revenue (+7% YoY) and improved adjusted EBITDA ($243M Q3) imply limited immediate share-loss risk; pricing power remains tied to product mix (pharma/surgical > retail contact lenses).

Risk assessment: Tail risks include a regulatory setback in ophthalmic pharmaceuticals (FDA action) or a surgical-device recall that could wipe out near-term margins — low-probability but high-impact within 6–12 months. Immediate risk (days) is headline-driven volatility; short-term (weeks/months) depends on follow-on 13F exits or earnings misses; long-term (quarters/years) hinges on sustained margin expansion and pipeline approvals. Hidden dependency: currency exposure and supply-chain concentration in manufacturing could compress margins if FX moves >5% or component costs rise materially.

Trade implications: Opportunistic, size-constrained long exposure to BLCO is warranted on weakness: allocate 1–2% portfolio if price falls to $13–$15, target 30–50% upside in 12–18 months if adjusted EBITDA continues rising and guidance is maintained. Implement options (cash-secured puts or 9–12 month calls) to improve entry, and consider a hedged pair (long BLCO, short XLV or a healthcare benchmark) to isolate idiosyncratic recovery while limiting beta. Avoid large outright shorts; liquidity and stock-specific events make aggressive shorts risky over earnings windows.

Contrarian angles: The consensus frames this as low conviction selling; that overlooks improving fundamentals — revenue growth and upward EBITDA guidance — so the reaction looks modestly overdone if broader healthcare sentiment stabilizes. Historical parallel: mid-cap medical-device names often recover within 6–18 months after transient institutional exits when fundamentals improve. Unintended consequence: crowded options selling into a dip could create asymmetric buying into calls; monitor open interest and 30-day IV spikes as a short-term contrarian signal.

Key Decisions for Investors

• Establish a small long position in Bausch + Lomb (BLCO) sized 1–2% of portfolio if price dips into $13–$15; set a hard stop at 15% below entry and an initial target of +30–50% over 12–18 months contingent on EBITDA >$250M next quarter and maintained revenue growth.
• Use options to improve entry: sell cash-secured puts BLCO strike $12 exp 6–9 months (collect premium, willingness to own at $12) or buy 12-month calls strike $17 capped at 0.5–1% portfolio notional to leverage upside while limiting downside.
• Implement a hedged pair to isolate idiosyncratic recovery: long BLCO (0.5–1% net) vs short XLV or equivalent healthcare ETF (delta-sized to neutralize beta) and rebalance monthly; close if BLCO outperforms by >30% or if XLV outperforms by >10% in 3 months.
• Risk-management triggers to act within 30–90 days: exit or cut position if (a) next quarter adjusted EBITDA misses consensus by >10%, (b) company issues an FDA warning/recall, or (c) multiple 13F filings show >5 institutional managers reducing BLCO positions sequentially.